| Q34763502 | A modified γ-retrovirus vector for X-linked severe combined immunodeficiency |
| Q92216646 | Abnormal submaximal cardiopulmonary exercise parameters predict impaired peak exercise performance in sickle cell anemia patients |
| Q52718038 | Angiotensin Receptor Signaling in Sickle Cell Anemia has a Reno-Protective effect on Urine Concentrating Ability but results in Sickle Glomerulopathy. |
| Q90282101 | Author Correction: Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity |
| Q93116167 | CRISPR-Cas9 fusion to dominant-negative 53BP1 enhances HDR and inhibits NHEJ specifically at Cas9 target sites |
| Q88751362 | Diastolic dysfunction is associated with exercise impairment in patients with sickle cell anemia |
| Q98240625 | Drug Therapies for the Management of Sickle Cell Disease |
| Q89532361 | Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity |
| Q48315547 | Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial. |
| Q39599891 | Perforin gene transfer into hematopoietic stem cells improves immune dysregulation in murine models of perforin deficiency |
| Q92151414 | Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia |